India's Glenmark completes PhI dosing for GBR 830; Chengdu launches Hi-tech Zone;

> India's Glenmark Pharmaceuticals' Swiss subsidiary has completed Phase I dosing for GBR 830, a monoclonal antibody candidate that is an antagonist of OX40, a costimulatory receptor aimed at autoimmune diseases, including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Release

> Japan's Kobe Biomedical Innovation Cluster will feature 8 biotech companies at the Medical Fair Thailand, Asia's largest medical device exhibition. The event takes place this weekend in Bangkok. Release

> China's Yabao Pharmaceutical has inked a pact with the University of South Australia on oncology treatment development that will identify candidates in a co-funded laboratory led by Professor Shudong Wang. The agreement includes funding from Yabao Pharmaceutical, which will gain exclusive rights to develop and commercialize any drug candidates in China. The University of South Australia retains rights in all other markets. Report

> China's Chengdu Hi-tech Zone was kicked off this month as part of Beijing's aim for a "Silk Road" development strategy that will include medical device and pharmaceutical makers that could receive tax preferences and other incentives to attract thousands of companies. Release

> China-focused HUYA Biosciences has announced an expanded Phase I clinical trial of HBI-8000 for HER-2 positive advanced or metastatic cancer patients in the U.S. Release

> India's plans for the government to open as many as 3,000 shops to sell cut-rate versions of generic medicines has been delayed by at least two months because manufacturers need more time to ramp up capacity, the Times of India said. Report